Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Revenue of Scilex Holding Company (SCLX)
Revenue in 2023 (TTM): $46.74 M
According to Scilex Holding Company's latest financial reports the company's current revenue (TTM) is $46.74 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Scilex Holding Company
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $46.74 M | $31.06 M | $-109,104,000 | $-114,318,000 | $-114,331,000 |
| 2022 | $38.03 M | $27.24 M | $-9,303,000 | $-23,360,000 | $-23,364,000 |
| 2021 | $31.32 M | $27.68 M | $-44,876,000 | $-88,419,000 | $-88,424,000 |
| 2020 | $23.56 M | $21.41 M | $-31,481,000 | $-47,572,000 | $-47,519,000 |
| 2019 | $21.03 M | $15.23 M | $-134,485,000 | $-178,592,000 | $-178,594,000 |